Affimed N.V. Stock – Fundamental Analysis
Not enough price data available yet.
Fundamental Data & Ratios (Balance sheet update: 4/3/2024)
| Balance Sheet | Total Assets | 24,000,000.00 | ROE | – |
| Balance Sheet | Total Equity | 12,000,000.00 | ROA | – |
| Cashflow | Capital Expenditures | -50,000.00 | P/FCF | – |
| Cashflow | Free Cash Flow | -75,050,000.00 | – | – |
| Cashflow | Operating Cash Flow | -75,000,000.00 | P/CF | – |
| Income | Earnings per Share (diluted) | -4.26 | Div. Yield | – |
| Income | Net Income | -66,000,000.00 | P/E | – |
| Income | Shares Outstanding | 15,493,000.00 | P/B | – |
| Income | Total Revenue | 700,000.00 | P/S | – |
Ratios calculated on: –
Company Description
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes FM13, AFM11, AFM21, AFM22, AFM24, TandAb and Trispecific Abs. It has started recruitment for Phase IIa clinical trial of AFM13 in patients with Hodgkin Lymphoma. It has initiated a Phase I clinical trial of AFM11 in patients with non-Hodgkin Lymphoma. AFM21 is in preclinical development. AFM22, which is an Epidermal Growth Factor Receptor variant III (EGFRvIII)/CD16A NK-cell TandAb is in preclinical development. AFM24 is an additional CD16A NK-cell TandAb targeting a validated solid tumor target, EGFR-wild type. It is developing Trispecific Abs for treating multiple myeloma, and CD33/CD3-specific T-cell TandAb to treat acute myeloid leukemia.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.affimed.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more